GlassScriptPhysician profile
Alexander Roussos
NPI 1700380607
$8,015.79
in general payments reported to CMS, 2019-2025
12 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,999 · 2023: $2,527 · 2024: $1,299 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,017.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,952.17 | 2022-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Abbott Laboratories | $1,321.16 | 2022-2024 | Proclaim, Eterna, Axium |
| Spr Therapeutics, INC | $736.90 | 2022-2023 | Sprint Pns System |
| Saluda Medical Americas, INC. | $455.73 | 2023-2024 | Evoke Scs, Evoke |
| Stryker Corporation | $391.08 | 2022-2023 | Spinejack |
| Nevro Corp. | $365.44 | 2022-2023 | Senza |
| Becton, Dickinson and Company | $255.66 | 2024-2025 | Hemosphere |
| Relievant Medsystems, INC. | $140.45 | 2022 | |
| Nalu Medical, INC. | $137.31 | 2023 | Nalu Neurostimulation System |
| Averitas Pharma INC. | $127.41 | 2023 | Qutenza |
| Mml US, INC. | $77.49 | 2023 | Reactiv8 |
| Boston Scientific Corporation | $54.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Roussos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.